| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Core protein II; QCR2; mitochondrial; Ubiquinol cytochrome c reductase core protein II; UQCR2; Uqcrc2; ;UQCRC2 |
| WB Predicted band size | 48 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human UQCRC2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于UQCRC2抗体的3篇示例参考文献(注：文献为假设性示例，实际引用需通过学术数据库验证)：
---
1. **文献名称**: *UQCRC2 mutations cause mitochondrial complex III deficiency with neurological impairment*
**作者**: Smith A, et al.
**摘要**: 本研究通过全外显子测序发现UQCRC2基因突变导致线粒体复合体III功能障碍，利用UQCRC2抗体进行Western blot和免疫组化分析，证实突变引起蛋白表达下降，与儿童神经退行性疾病相关。
---
2. **文献名称**: *Antibody-based profiling of mitochondrial respiratory chain complexes in human cancers*
**作者**: Lee B, et al.
**摘要**: 开发了一种基于UQCRC2抗体的多重免疫检测方法，用于分析肿瘤样本中线粒体复合体III的表达水平，发现其在乳腺癌和结直肠癌中显著下调，提示其作为潜在生物标志物的可能性。
---
3. **文献名称**: *Functional characterization of UQCRC2 in Parkinson’s disease models*
**作者**: Chen X, et al.
**摘要**: 使用UQCRC2抗体研究帕金森病模型中线粒体功能，发现UQCRC2与α-突触核蛋白异常聚集相关，基因敲低导致多巴胺能神经元活性氧积累，加剧细胞死亡。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词“UQCRC2 antibody”或“UQCRC2 mitochondrial complex III”，筛选近5年相关研究。
The UQCRC2 antibody targets the Ubiquinol-Cytochrome c Reductase Core Protein 2 (UQCRC2), a key subunit of mitochondrial Complex III (cytochrome bc1 complex) in the electron transport chain (ETC). Complex III plays a critical role in oxidative phosphorylation by transferring electrons from ubiquinol to cytochrome c and pumping protons to establish the mitochondrial membrane potential, driving ATP synthesis. UQCRC2. encoded by the nuclear UQCRC2 gene, is a core structural component of Complex III, forming a dimer with UQCRC1 to stabilize the complex’s structure and facilitate interactions with other ETC components.
Mutations or dysregulation of UQCRC2 are linked to mitochondrial disorders, neurodegenerative diseases (e.g., Parkinson’s), and cancer. Reduced UQCRC2 expression impairs ETC function, leading to energy deficits, oxidative stress, and apoptosis. Antibodies against UQCRC2 are widely used in research to study mitochondrial health, protein localization (via immunofluorescence or immunohistochemistry), and expression levels (via Western blotting). They also aid in investigating diseases associated with mitochondrial dysfunction, such as Leigh syndrome, cardiomyopathy, and metabolic syndromes. Commercial UQCRC2 antibodies are typically validated for specificity in human, mouse, or rat samples, supporting both basic research and clinical diagnostics.
×
